Very often, the joys of pregnancy are accompanied by questions such as: is my baby developing properly, is it healthy, and is there anything more I can do to ensure its future? <\/p>\n\n\n\n
VERAgene is a new-generation, non-invasive prenatal test that helps expectant parents find out more at an early stage. It analyses the mother\u2019s blood and a cheek swab from the father, enabling the assessment not only of the most common chromosomal abnormalities, such as Down\u2019s, Edwards\u2019 and Patau\u2019s syndromes, but also selected microdeletions and over 100 monogenic disorders. <\/p>\n\n\n\n
This programme is for parents who want to take a broader view of their child\u2019s health and navigate the first few weeks of pregnancy with greater mindfulness. <\/p>\n\n\n\n
The VERAgene test is a modern prenatal screening test which, like the VERACITY Advanced test (link), falls within the NIPT (Non-Invasive Prenatal Testing) category. Both tests use an advanced method of analysing free foetal cell-free DNA, which circulates in the mother\u2019s blood, to detect potential genetic abnormalities. <\/p>\n\n\n\n
The VERAgene test is distinguished by its broader diagnostic scope, enabling it to identify not only aneuploidies (i.e. changes in chromosome number), but also selected microdeletions and a panel of 100 single-gene diseases. <\/p>\n\n\n\n
Thanks to the technology used, the VERAgene test enables the extremely precise detection of minimal differences in DNA. This method of analysis allows for an accurate assessment of the risk of various chromosomal abnormalities in the foetus, including trisomy and rare microdeletions. Importantly, the VERAgene test also utilises the advanced TACS (Total Aneuploidy and Chromosomal Syndrome) analysis method. This enables even more accurate detection of very subtle changes in DNA structure, which may indicate the presence of serious genetic disorders.\u00a0<\/p>\n\n\n\n
The VERAgene test is a hybrid test which is not limited to analysing the mother\u2019s blood, but also takes into account a swab from the partner\u2019s mouth, allowing for an even more comprehensive assessment of potential genetic risks to the baby.\u00a0<\/p>\n\n\n\n
This sophisticated and highly advanced technique enables us to obtain precise information about the child\u2019s health. It is possible to detect selected trisomies, aneuploidies and microdeletions in the foetus, as well as 100 monogenic disorders. These disorders are responsible, amongst other things, for congenital defects, visual or hearing impairments, and abnormal development. Before NIPT tests became available on the market, similar results could only be obtained through invasive tests, which carry a small risk of miscarriage.\u00a0<\/p>\n\n\n\n
Abnormalities associated with the presence of an extra copy or the absence of a single copy of a chromosome<\/strong>:\u00a0<\/p>\n\n\n\n Disorders associated with the absence of a single, small segment of the DNA strand, known as microdeletions<\/strong>\u00a0including, amongst others:\u00a0<\/p>\n\n\n\n 100 diseases associated with a defect within a single gene, known as<\/strong>. monogenic disorders, including: <\/p>\n\n\n\n In addition, the VERAgene test allows the sex of the baby to be determined at the patient\u2019s request. <\/p>\n\n\n\n The VERAgene test is recommended for all pregnant women from the 9th week onwards, regardless of whether the pregnancy is natural or has been achieved through assisted reproductive technologies, including in vitro fertilisation (IVF). The test can be carried out in both single and twin pregnancies. <\/p>\n\n\n\n VERAgene is the first hybrid test on the market to combine NIPT with the analysis of genetic material from both parents. The samples analysed consist of two tubes of the mother\u2019s blood and a cheek swab from the child\u2019s biological father. <\/p>\n\n\n\n The study is particularly recommended if:<\/strong> <\/p>\n\n\n\n\n
\n
\n
Who is the VERAgene test aimed at?\u00a0<\/h2>\n\n\n\n
\n